Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nusinersen in Adult 5q-SMA Type 2 or 3
NCT04576494Completed
- Sponsor
- CHU de Reims
- Start
- Jan 2022
- Primary completion
- Jan 2023
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Randomised, single-blind trial of nusinersen in spinal muscular atrophy type 2 (SMA2) and Spinal muscular atrophy type 3 (SMA3), sponsored by CHU de Reims. Primary endpoint: Functional Motor Ability at 19 months. Started Jan 2022; status: completed.
02
Drugs
nusinersen
03
Conditions
spinal muscular atrophy type 2 (SMA2)Spinal muscular atrophy type 3 (SMA3)
Beyond the preview
Go deeper on NCT04576494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04576494.